The British government has awarded Intercytex a grant to automate the production of their new hair regeneration therapy. Intercytex is a cell therapy company that develops products to restore and regenerate skin and hair. Intercytex has partnered with a private company, The Automation Partnership (TAP), to develop an automated manufacturing process for their novel hair multiplication treatment.
The hair multiplication product, ICX-TRC, has been submitted as a hair regeneration therapy that uses cells cloned from one’s own scalp. It is intended for the treatment of male pattern baldness (androgenetic alopecia) and female pattern hair loss. The key researcher, biochemist Dr. Paul Kemp, founder of Intercytex, is developing the hair multiplication treatment at their Manchester facility. This investment in hair cloning research is spearheaded by UK Science Minister, Lord Sainsbury.
The government grant will be used mainly to develop a robotic system specifically designed to support the commercial-scale production of their hair cloning product ICX-TRC, at a scale that can handle a large number of people. The company is currently in Phase II clinical testing.
How Intercytex’s Hair Cloning Product Works
Intercytex’s method of hair regeneration involves removing a slice of the scalp, complete with hairs and follicles, from the back of the head. Hair follicles from this area are most resistant to typical hereditary baldness. The sample is taken to a laboratory where the hair producing dermal papilla (DP) cells are extracted and multiplied in flasks. After eight weeks, the DP cells should have cloned into millions of hair cells.
To complete the hair cloning process, the new cells are injected back into the patient’s scalp under a local anesthetic. These cultured cells should then develop into brand new hair follicles.
Intercytex is a 6-year-old company with its main office is in Cambridge, UK and has a clinical production facility and research and development laboratories in Manchester, UK. Additional laboratories are located in Boston, Massachusetts. TAP, founded in 1988, is a private company with headquarters near Cambridge, UK. Intercytex is publicly traded on the London Stock exchange (LSE: ICX).
Additional information about this hair cloning product can be found at www.intercytex.com.
- Researchers Untangle Potential Pathway to Regenerating Hair in a Bald Scalp
- Study More Accurately Predicts Severe Balding Risk Using New Genetic Profile
- JAK Inhibitors Prove Effective in Trials on Alopecia Areata
- Viviscal May Boost Hair Regrowth
- Viviscal Research Suggests the Treatment Increases Hair Volume, Thickness
Tags: Androgenetic Alopecia, Dermal Papilla, Female Pattern Hair Loss, Hair Cloning, Hair Cloning News, Hair Follicle, Hair Multiplication, Hair Regeneration, Intercytex, Male Pattern Baldness, Male Pattern Hair Loss, UK Posted by